Compare Gilead Sciences, Inc. (GILD) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ferrari NV — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $163.51B), while Ferrari NV trades at $382.35 (market cap $65.93B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Ferrari NV's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RACE | |
|---|---|---|
Market Cap | $163.51B | $65.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $517.65 |
52-Week Low | $108.22 | $314.63 |
Enterprise Value | $178.05B | $67.14B |
Dividend Yield | 2.49% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Ferrari (RACE) trades at $381.51, up 3.35% today, with a bullish technical signal from moving averages and strong fundamentals including 22.19% net income margin and 41.96% ROE. Recent earnings beats and a $3.62 dividend highlight operational strength, while a multi-year share buyback program and upcoming Q2 2026 results on July 30, 2026 (GlobeNewsWire, 2026-07-15) provide near-term catalysts.
The outlook remains positive given analyst consensus price target of $467.50 (72.22% buy ratings), though high valuation multiples (P/E 36.7) and EV transition risks pose challenges. Stock investors may find opportunity in Ferrari's pricing power and margin resilience, balanced against macroeconomic sensitivity and execution risks on new models.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
